Quince Therapeutics, Inc.
$1.27
▼
-3.23%
2026-04-21 09:01:01
www.quincetx.com
NMS: QNCX
Explore Quince Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$22.33 M
Current Price
$1.27
52W High / Low
$45.5 / $0.8
Stock P/E
—
Book Value
$0.02
Dividend Yield
—
ROCE
-33.74%
ROE
-2.48%
Face Value
—
EPS
$-12
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
36
Beta
1.33
Debt / Equity
1,699.06
Current Ratio
1.12
Quick Ratio
6.05
Forward P/E
-0.12
Price / Sales
—
Enterprise Value
$-0.71 M
EV / EBITDA
0.02
EV / Revenue
—
Rating
None
Target Price
$0
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Iovance Biotherapeutics, Inc. | $3.78 | — | $1.56 B | — | -51.39% | -55.5% | $5.63 / $1.64 | $1.7 |
| 2. | Bio-Techne Corporation | $59.22 | 116.91 | $9.33 B | 0.53% | 10.19% | 3.97% | $72.16 / $46.01 | $12.9 |
| 3. | Candel Therapeutics, Inc. | $7.22 | — | $466.58 M | — | -41.46% | -64.58% | $7.25 / $4.34 | $0.95 |
| 4. | Ginkgo Bioworks Holdings, Inc. | $7.98 | — | $492.71 M | — | -29.68% | -51.08% | $17.58 / $5.37 | $8.74 |
| 5. | Cytokinetics, Incorporated | $65.05 | — | $8.11 B | — | -50.1% | 197.47% | $70.98 / $29.31 | $-5.37 |
| 6. | Replimune Group, Inc. | $2.07 | — | $170.93 M | — | -53.14% | -90.88% | $13.24 / $1.5 | $2.64 |
| 7. | RenovoRx, Inc. | $1 | — | $45.05 M | — | -176.68% | -2.26% | $1.45 / $0.7 | $0.15 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -11.36 M | -9.89 M | -12.93 M | -10.11 M | -8.55 M |
| Net Profit | -13.44 M | -16.05 M | -15.03 M | -12.46 M | -5.49 M |
| EPS in Rs | -2.41 | -2.88 | -2.7 | -2.24 | -0.99 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -36.17 M | -27.14 M | -51.19 M | -90.32 M |
| Net Profit | -56.83 M | -31.39 M | -51.66 M | -89.94 M |
| EPS in Rs | -10.21 | -5.64 | -9.28 | -16.15 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 114.48 M | 167.9 M | 103.91 M | 133.23 M |
| Total Liabilities | 84.33 M | 82.82 M | 3.32 M | 14.64 M |
| Equity | 30.15 M | 85.08 M | 100.59 M | 118.59 M |
| Current Assets | 44.04 M | 77.44 M | 93.75 M | 111.67 M |
| Current Liabilities | 7.28 M | 9.57 M | 3.07 M | 14.22 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -31.9 M | -18.29 M | -44.04 M | -62.93 M |
| Investing CF | 21.91 M | -5.76 M | 18 M | 58.95 M |
| Financing CF | -4.78 M | 0.14 M | 0.71 M | 6.81 M |
| Free CF | -32.16 M | -18.45 M | -44.17 M | -63.11 M |
| Capex | -0.26 M | -0.16 M | -0.13 M | -0.18 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -81.07% | 39.25% | 42.56% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.